BDD accelerates FDA engagement and collaboration — it does not lower the evidentiary bar. Here's how to build a regulatory strategy around what it actually does.
An FDA deficiency letter isn't a rejection, but a disorganized non-targeted response can function like one. Here's a strategic framework for responding without stalling your review.
6 min read
Are you pressed for time?
Reach out to discuss our priority project pricing.
